2Seventy Bio

2seventy Bio, Inc. operates as cell and gene therapy company. It is focused on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

2Seventy Bio reports solid Q2 revenue, navigates competitive challenges

2Seventy Bio's Q2 2023 performance reflects strong revenue driven by ABECMA, with a focus on innovation and patient care. The company faces challenges from competitive dynamics and FDA clinical holds but is strategically positioned to capitalize on opportunities in the oncology space.

2Seventy Bio addresses challenges, highlights ABECMA support at Q3 call

2Seventy Bio navigated a challenging quarter with a focus on ABECMA support and organizational reshaping.
Key presentations at ASH showcased positive outcomes for ABECMA, while concerns around growth and profitability were addressed.
Management's commitment to stakeholders and strategic partnerships position the company for future growth and success.

2Seventy Bio reports robust Q4 earnings, eyes growth opportunities

2Seventy Bio's Q4 2023 earnings call highlighted strong financial performance, cost-saving initiatives, and confidence in Abecma's market potential.
While facing competition challenges and operational considerations, the company remains focused on growth, innovation, and financial sustainability.
Strategic partnerships, upcoming regulatory milestones, and a clear roadmap to breakeven underscore 2Seventy Bio's commitment to long-term success.

2Seventy Bio focuses on Abecma growth post realignment

2Seventy Bio's Q1 2024 performance was solid, with Abecma revenues meeting expectations.
The company's strategic realignment towards Abecma aims for cost efficiency and growth.
Challenges lie in achieving breakeven by 2025 and sustaining Abecma's market position.
Opportunities exist for increased profitability, market expansion, and operational efficiency.

2Seventy Bio focuses on ABECMA, reports strong Q2 earnings

2Seventy Bio's Q2 performance reflects a strategic shift towards profitability and sustainable growth.
The company's strong financial results and cost-saving measures position it well for future success.
While challenges exist, opportunities in product focus and financial management pave the way for a promising future.
Overall, 2Seventy Bio's focus on ABECMA and profitability sets a positive trajectory for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

2seventy Bio, Inc. operates as cell and gene therapy company. It concentrates on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.

MARTINSRIED, Germany and MUNICH, Germany, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Martinsried -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology company focused on the development of differentiated, best-in-class T Cell Receptor engineered T cell (TCR-T) therapies, today announced that it has received a $3 million milestone payment from its partner 2seventy bio as part of its T cell receptor agreement in cancer immunotherapy, and which may lead to further potential milestone payments in the future. This payment follows the strategic alliance between 2seventy bio (Nasdaq: TSVT), and JW Therapeutics (HKEX: 2126), with the initial focus on the development of 2seventy bio's MAGE-A4 program which employs a highly potent TCR discovered in collaboration with Medigene's proprietary end-to-end technology platform.

Medigene Receives $3 Million Milestone Payment from 2seventy bio

CAMBRIDGE, Mass.--( BUSINESS WIRE )--2seventy bio, Inc. (Nasdaq: TSVT) announced today key corporate milestones and financial outlook for 2023.

2seventy bio Provides Company Outlook for 2023

TORONTO--( BUSINESS WIRE )--Deep Genomics, a leading AI drug development company focused on decoding biology to program life-changing medicines, today announced additions to its Board of Directors and Scientific Advisory Board which will advance its capabilities to develop oligonucleotides designed to boost protein production across a broad range of genetically driven diseases. New to the Board of Directors are Jacqueline Fok, Ph.D., Investment Vice President at SoftBank Vision Fund, Nessan Bermingham, Ph.D., Operating Partner at Khosla Ventures, and William Baird, Chief Financial Officer at 2Seventy Bio. Oligonucleotide authorities Arthur M. Krieg, M.D. and Mark Edbrooke, Ph.D. have joined the Scientific Advisory Board.

Biotech Industry Leaders Join Deep Genomics Board of Directors and Scientific Advisory Board

CAMBRIDGE, Mass.--( BUSINESS WIRE )--2seventy bio, Inc. (Nasdaq: TSVT) today announced an amendment to its collaboration with Regeneron that will facilitate an expanded and accelerated development plan for novel cell therapy-based combinations for solid tumors. The collaboration will leverage 2seventy bio's unique cell therapy engineering and early-stage development capabilities, including the newly built in-house clinical cell therapy manufacturing facility, with Regeneron's differentiated antibodies and bispecifics.

2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid Tumors

Abecma U.S. sales in Q3 by BMS were $75 million. 2seventy bio is working on label expansion for Abecma.

2seventy bio A Buy For Abecma And CAR T Platform

2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of -1.15% and 25.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

2seventy bio, Inc. (TSVT) Reports Q3 Loss, Tops Revenue Estimates

2seventy bio to Present Data from KarMMa-2 Study of Abecma (idecabtagene vicleucel) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

The average of price targets set by Wall Street analysts indicates a potential upside of 96.9% in 2seventy bio, Inc. (TSVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does 2seventy bio, Inc. (TSVT) Have the Potential to Rally 97% as Wall Street Analysts Expect?

2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies

Shares have lost over 40% of their value since the spinoff in November. The pipeline has multiple shots on goal including in solid tumors and AML plus validating partnerships via Regeneron and BMY.

2seventy Bio: This Spinoff In The CAR-T Space Is Attractive

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) today announced plans to initiate the KarMMa-9 study to evaluate Abecma (idecabtagene vicleucel) in newly diagnosed multiple myeloma patients who have suboptimal response to transplant. The company, in partnership with Bristol Myers Squibb, plans to provide additional information about the design and timing of the study at the earliest upcoming opportunity. “Our focus at 2seventy is giving as much time as possible to patients

2seventy bio Announces Plans to Initiate KarMMa-9 Study of Abecma (idecabtagene vicleucel) in Newly Diagnosed Multiple Myeloma Patients

Abecma, a CAR-T myeloma therapy, is rapidly ramping revenue. 2seventy has $398 million in cash.

2seventy bio Prospects

Shoals Technologies Group

BJ`s Wholesale Club Holdings Inc

The RealReal

Wayfair

It's important to know which quantitative factors make a stock worthwhile. These five have the attributes needed for success.

The 5 Top Profit & Protection Stocks to Buy for 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) announced today that it will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 14, 2022 at 3:20pm PT. A live webcast will be available via the Investors and Media section of 2seventy bio's website at https://ir.2seventybio.com/. A replay will be archived on 2seventy bio's site for 30 days following the event. About 2seventy bio Our name, 2se

2seventy bio to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, will present preclinical data on bbT369, an investigational novel CD79a/CD20 dual-targeting CBLB gene edited CAR T cell therapy at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA. These data will be presented in a poster session (poster #581) on Sunday, April 10, 1:30-5:30 PM CT. “While anti-CD19 CAR T cell therapies have improved outco

2seventy bio Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, at the AACR Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) announced today that it will present at the CG Horizons in Oncology Virtual Conference, on the Attacking AML: New Approaches Panel on Thursday, April 14, 2022 at 1:30pm ET. Live webcasts of presentations will be available via the Investors and Media section of 2seventy bio's website at https://ir.2seventybio.com/. A replay of each presentation will be archived on 2seventy bio's site for 30 days following the event. About 2seve

2seventy bio to Participate in CG Horizons in Oncology Virtual Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2021. “We launched 2seventy bio at the end of 2021 with incredible starting material. We have a transformative commercial product in ABECMA, a pipeline with multiple clinical stage programs, next-generation technologies that will enable us to continue to be at the forefront

2seventy bio Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, announced today that it has agreed to sell approximately 13,934,427 shares of its common stock to a select group of institutional and accredited investors in a private placement. Upon the closing of the financing, 2seventy bio will receive gross proceeds of approximately $170 million, before payment of offering commissions and expenses, based on a price of $12.20 per share, the

2seventy bio Secures $170 Million in Private Placement Equity Financing

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (NASDAQ: TSVT) announced that Steven Bernstein, M.D. will join the company effective today and assume the role of chief medical officer (CMO). Also announced today, Susan Abu-Absi, Ph.D. has been appointed chief technology & manufacturing officer at 2seventy bio. “We are thrilled to welcome Steve to the 2seventy team as we bring our next-generation cell therapy product engine to the clinic. He brings both experience as a treating heme/on

2seventy bio Announces Key Management Appointments

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT) announced today that it will present at the following upcoming investor conferences: SVB Leerink 10th Annual Global Healthcare Conference; Fireside chat, Wednesday, February 16, 2022, at 2:20pm ET Cowen Virtual 42nd Annual Healthcare Conference; “Novel Oncology Targets” panel, Monday, March 7, 2022, at 12:50pm ET Live webcasts of presentations will be available via the Investors and Media section of 2seventy bio's website at h

2seventy bio to Participate in Upcoming Healthcare Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT), an emerging immuno-oncology cell therapy company, today provided an update on the company's outlook for 2022. “It has been a privilege to launch 2seventy bio with such a strong foundation out of the gate including a first-in-class CAR-T for multiple myeloma with $1-2B late lines global peak sales potential, a highly differentiated product engine already delivering candidates to the clinic, strong financial health with a disci

2seventy bio Shares Key Milestones and Business Updates for 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (NASDAQ:TSVT) today announced that it has entered into an option and license agreement with Novo Nordisk for joint research and development of an in vivo gene editing treatment for hemophilia A. This agreement builds upon a successful existing multi-year research collaboration between the two companies. Under the terms of this agreement, Novo Nordisk will have the option to license 2seventy bio's proprietary mRNA-based megaTAL™ technology fo

2seventy bio Announces Expanded Collaboration Agreement With Novo Nordisk to Continue Development of in vivo Gene Editing Approach

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (NASDAQ: TSVT) today announced data from its broad oncology cell therapy portfolio, including updated results from the CRB-402 study of bb21217 and new analyses from the pivotal KarMMa study of ABECMA® (idecabtagene vicleucel; ide-cel) for adult patients with relapsed or refractory multiple myeloma, both in partnership with Bristol Myers Squibb (BMS). The company also presented preclinical data on the investigational CD33-targeted autologous

2seventy bio Presents Data Across Multiple Cell Therapy Programs at ASH 2021 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) announced today that it will participate in a fireside chat at the 5th Annual Cowen IO Next Summit on November 15, at 1:15pm ET. A webcast of the presentation will be available via the investor relations section of the 2seventy bio website for 30 days following the event. About 2seventy bio Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away and our goal is to work at the maximum speed of transl

2seventy bio to Present at the 5th Annual Cowen IO Next Summit

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (NASDAQ: TSVT) announced today that data from its pipeline of oncology cell therapies will be presented, including two oral presentations, at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition on December 11-14, 2021, in Atlanta, Georgia and virtually. New pre-clinical data on SC-DARIC33, an investigational, pharmacologically controlled CD33-targeted chimeric antigen receptor (CAR) T cell product, being studied and d

2seventy bio to Present Data from its Portfolio of Oncology Cell Therapies at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition

News for 2Seventy Bio Stock (TSVT)